InCoax shifts to direct sales focus under revised Nokia cooperation plan
Bitget2026/10/05 06:35InCoax Networks AB pivoted to direct sales, shifting resources from development and integration toward customer acquisition. Reworked Nokia cooperation targets InCoax-led sales, lifting restrictions that limited direct outreach to previously identified customers. Commercial focus to narrow to selected customers and projects, aiming for faster deal cycles and higher contribution per transaction. Plan targets a substantial cut in development costs, supported by a more flexible, carrier-grade platform built during prior work. With TO2 warrants unexercised at SEK 0.60, InCoax is pursuing alternative funding, expecting new capital before end-2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InCoax Networks AB published the original content used to generate this news brief via Cision (Ref. ID: 202610050235BITN____UKPR__EN_20261004-BIT-8812-0) on October 05, 2026, and is solely responsible for the information contained therein.
- InCoax Networks AB pivoted to direct sales, shifting resources from development and integration toward customer acquisition.
- Reworked Nokia cooperation targets InCoax-led sales, lifting restrictions that limited direct outreach to previously identified customers.
- Commercial focus to narrow to selected customers and projects, aiming for faster deal cycles and higher contribution per transaction.
- Plan targets a substantial cut in development costs, supported by a more flexible, carrier-grade platform built during prior work.
- With TO2 warrants unexercised at SEK 0.60, InCoax is pursuing alternative funding, expecting new capital before end-2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Ethereum Price Prediction Eyes $3,500 Before $60K Macro Target
Crypto prices
More
